Stock Updates

Is this Large Market Cap Stock target price reasonable for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)?

The company in question is, Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) currently with a stock price of 411 (-0.17% today). The market cap for Regeneron Pharmaceuticals, Inc. is 43329.32, and is in the sector Healthcare, and Biotechnology industry. The target price for Regeneron Pharmaceuticals, Inc. is 466.64. Currently Regeneron Pharmaceuticals, Inc. is trading with a P/E of 64.26, and a forward P/E of 28.53. Average volume for Regeneron Pharmaceuticals, Inc. is 864.87 and so far today it is 270419.

Performance in the last year for Regeneron Pharmaceuticals, Inc. has been -27.73%. For EPS growth, Regeneron Pharmaceuticals, Inc. has seen a growth of 85.10%, and is looking to grow in the next year to 31.79%. More long term stats show that EPS growth has been 44.90% over the last five years and could be 18.62% for the next five years. Regeneron Pharmaceuticals, Inc. has seen sales growth quarter over quarter at 21.40%, with EPS growth quarter over quarter at 0.00%. The 20-day simple moving average is 6.76%, with the 200-day simple moving average coming to -4.71%.

Since the IPO date for Regeneron Pharmaceuticals, Inc. on the 4/2/1991, Regeneron Pharmaceuticals, Inc. has seen performance year to date to be -24.17%. With Regeneron Pharmaceuticals, Inc. trading at 411, the dividend yield is *TBA, and the EPS is 6.41.

So could Regeneron Pharmaceuticals, Inc., be undervalued? Well as said before P/E is 64.26. The PEG is 3.45, P/S is 9.32 and the P/B is at 10.57. The P/cash is 41.46, with P/free cash flow at 41.17.

Regeneron Pharmaceuticals, Inc. ability to deal with debt shows that the current ratio is 3.4, and the quick ratio is 3.1. This is with long term debt/equity at 0.09, and total debt/equity at 0.09.

In terms of margins, Regeneron Pharmaceuticals, Inc. has a gross margin of 91.40%, an operating margin of 33.80% and a profit margin of 19.50%.Payout ratio for Regeneron Pharmaceuticals, Inc. is 0.00%. Return on assets come to 15.90% with return on investment coming to 16.00%.

Insider ownership for Regeneron Pharmaceuticals, Inc., is at 0.50% and institutional ownership comes to 72.20%. Outstanding shares are at 105.25. While shares float is 77.55. The float short is currently 4.68%, and short ratio is 4.2.

Disclaimer: Remember there is a risk to your investment, this is not a recommendation, nor personal advice, never invest more than you are able too loose.

About the author

Tony Dabbs

Leave a Comment